ArticleOpen life sciences2026
SRPX2 exhibits neuroprotective effects in neural stem cells: inhibition of OGD/R-stimulated apoptosis and oxidative stress.
Article in Open life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypoxic-ischemic encephalopathy (HIE) is a major cause of infant morbidity as well as mortality. Neural stem cells (NSCs) is essential for brain development and function, and the role of NSCs in HIE is crucial and deserves further study. Sushi repeat-containing protein X-linked 2 (SRPX2) is a novel chondroitin sulfate proteoglycan which has multiple biological functions, such as cell growth and adhesion. However, SRPX2 is rarely reported in HIE process, and the mechanism is unclear. Herein, we aimed to uncover the role of SRPX2 in the progression of HIE. The oxygen-glucose deprivation/reoxygenation (OGD/R) model was established as a HIE cell model. We revealed that SRPX2 improves survival of OGD/R-stimulated NSCs. SRPX2 inhibited apoptosis of OGD/R-stimulated NSCs. Further data confirmed SRPX2 restrained oxidative stress of OGD/R-stimulated NSCs. Mechanically, SRPX2 activated the Wnt/beta-catenin pathway, and therefore suppressed the apoptosis as well as oxidative stress of OGD/R-stimulated NSCs. Collectively, SRPX2 suppressed apoptosis as well as oxidative stress of OGD/R-stimulated NSCs by activating Wnt/β-Catenin pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.